Evidence map›Paper›PMID 35482444›Full record

ArticleJournal of medicinal chemistry2022

Mechanistic Studies and

George A Naclerio, Nader S Abutaleb, Kenneth I Onyedibe, Caroline Karanja, Hassan E Eldesouky, Hsin-Wen Liang, Alexandra Dieterly, Uma K Aryal, Tiffany Lyle, Mohamed N Seleem and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

George A NaclerioChemistry Department, Institute for Drug Discovery, Purdue University, West Lafayette, Indiana 47907, United States.
Nader S AbutalebDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24060, United States.ORCID 0000-0003-1730-4150
Kenneth I OnyedibeChemistry Department, Institute for Drug Discovery, Purdue University, West Lafayette, Indiana 47907, United States.
Caroline KaranjaChemistry Department, Institute for Drug Discovery, Purdue University, West Lafayette, Indiana 47907, United States.
Hassan E EldesoukyDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24060, United States.
Hsin-Wen LiangDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24060, United States.
Alexandra DieterlyDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana 47907, United States.
Uma K AryalDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana 47907, United States.ORCID 0000-0003-4543-1536
Tiffany LyleDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana 47907, United States.
Mohamed N SeleemDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24060, United States.ORCID 0000-0003-0939-0458
Herman O SintimChemistry Department, Institute for Drug Discovery, Purdue University, West Lafayette, Indiana 47907, United States.ORCID 0000-0002-2280-9359
Purdue University West Lafayette · USVirginia–Maryland College of Veterinary Medicine · US

Funding

Repurposing auranofin and ebselen for treatment of multidrug resistant pathogensR01AI130186 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI SELEEM, MOHAMED · 2017 to 2021
$2.3M
Drug Discovery in Infectious Disease TrainingT32AI148103 · NIAID · PURDUE UNIVERSITY · PI STAHELIN, ROBERT VIRGIL, YEO, YOON · 2020 to 2024
$949k
NIAID NIH HHS R01 AI130186NIAID NIH HHS T32 AI148103
6 · The paper itself

Abstract

Methicillin-resistant

Indexed as

Methicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsAnimalsAnti-Bacterial AgentsMiceMicrobial Sensitivity TestsOxadiazolesStaphylococcus aureusAnti-Bacterial AgentsOxadiazoles

Identifiers

PMID35482444
PMCPMC9124606
OpenAlexW4225109333

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.